Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients by Dranitsaris, George & Hatzimichael, Eleftheria
REVIEWARTICLE
Interpreting results from oncology clinical trials:
a comparison of denosumab to zoledronic acid
for the prevention of skeletal-related events
in cancer patients
George Dranitsaris & Eleftheria Hatzimichael
Received: 17 October 2011 /Accepted: 2 April 2012 /Published online: 27 April 2012
# The Author(s) 2012. This article is published with open access at Springerlink.com
Abstract
Background Critically reviewing the design, endpoints, and
results of clinical trials can be challenging to health care
professionals. This paper will review the basic methods of
presenting clinical outcomes in randomized trials and will
focus on the number needed to treat (NNT) concept. NNT
will then be applied to the case of bone-targeted therapies
denosumab and zoledronic acid, which are used for the
prevention of skeletal-related events (SREs) in a variety of
disease sites.
Methods A Medline search was performed to identify ran-
domized trials comparing denosumab to zoledronic acid for
the prevention of SREs in patients with advanced breast,
prostate, and other cancer sites. The data were extracted, and
point estimates for the primary and secondary trial endpoints
were converted into the NNT parameter.
Results NNT represents the number of patients that need
to be treated with a new intervention in order to avoid one
additional patient developing the event and is a powerful
approach that can be used to make sense of numerical
results from clinical trials. In patients with advanced
breast, prostate, and other cancer sites, 18, 22, and 21
patients, respectively, would need to be treated with deno-
sumab for at least 24 months to avoid one patient devel-
o p i n ga nS R E .
Conclusions The NNT approach is a simple and effective
method to express the findings of randomized trials in a clin-
ically meaningful way. In this analysis, the incremental benefits
of denosumab would be realized when a minimum of 18 to 22
patients are treated for a prolonged duration. Clinicians would
have to weigh the costs and benefits between denosumab and
zoledronic acid when bone-targeted therapy is indicated.
Keywords Numberneededtotreat .Denosumab .
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Introduction
Randomized controlled trials remain the gold standard for
assessing the efficacy of new drugs. Yet, it is not always
clear how to effectively interpret and use the trial findings.
Health care decision-makers must choose methods to inter-
pret data that are appropriate for the clinical question they
wish to address. Various outcome measures such as event
rates, relative risk (RR), relative risk reduction (RRR), ab-
solute risk reduction (ARR), odds ratios (OR), and hazard
ratios (HR) can be useful for understanding trial data from
an epidemiological viewpoint and in setting expectations for
aggregate clinical endpoints [20]. Such analyses may differ
in scope between health policy issues, drug regulatory ap-
proval, or patient-specific clinical decisions. The current
paper explains the number needed to treat (NNT) and num-
ber needed to harm (NNH) methods of analyses and dis-
cusses their virtues and potential pitfalls. The concepts are
applied to a real-world example comparing two drugs, zole-
dronic acid and denosumab, both approved for the preven-
tion of skeletal-related events (SREs) in various types of
cancer patients.
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In clinical research, many outcomes are presented as binary
(yes/no) and categorical outcomes. One of the most com-
monly used methods for analyzing binary data is the 2×2
contingency table (Table 1). Suppose that we are testing the
ability of a new drug to prevent disease recurrence in high-
risk cancer patients receiving adjuvant chemotherapy.
Twohundred patientswho meetthe study inclusion criteria
are randomized into an experimental group where the new
drugisgivenorintoacontrolgroupwheresubjectsreceivethe
current treatment standard (100 subjects in each group). The
primary objective of the trial is to compare the proportion of
patients in each group who experience disease recurrence at
5 years. Let us assume that the results of the study reveal that
25 % of patients in the experimental group experience disease
recurrence compared to 35 % in the control group.
Several methods can be used to describe these findings
(Table 2). Some of the most commonly used measures of
treatment effect include RR, RRR, ARR, and OR [9, 10, 12,
13]. Mathematically, RR is the incidence of an event in the
experimental group divided by the incidence in the control
group. In this example, the RR for disease recurrence with
the new drug in the experimental group is ~0.71 (i.e., 0.25/
0.35). This suggests that the risk of recurrence in the exper-
imental group is lower compared to the control group. RRR
is one minus the RR and is usually expressed as a percent-
age. In the chemotherapy example, the RRR for disease
recurrence with the new drug is 1–0.71 or 29 % [9, 10, 12,
13]. Another very useful measure of benefit in binary data
analysis is the ARR, which is the event rate in one group
minus that in the other group (Table 2). In the current
example, the ARR is 0.10 (i.e., 0.35−0.25).
Number needed to treat
What makes the ARR useful is that if the reciprocal (ARR
−1)
is taken, one can estimate the number of patients that need to
betreatedwith the newtherapy toavoid one additionalpatient
developing the event [9, 10, 12, 13]. To illustrate this point
using the above example, 10 patients would need to be treated
with the new chemotherapeutic agent to avoid one additional
patient with disease recurrence (i.e., 1/0.10010). However, if
the new therapy was only 1 % better than the standard, 100
patients would need to be treated to derive the same benefit
(i.e., 1/0.010100). The value of the ARR and NNT becomes
apparent in cost–benefit studies.
The advantage of NNT over other measures of clinical
benefit is that it can easily be understood in terms of medical
resource allocation by estimating how many patients would
needtoreceivethenewinterventioninordertoderiveaunitof
benefit [9, 10, 12, 13]. In order for the NNT to provide
meaningful estimates, it must always be considered relative
to a comparator group over a defined time period; NNTs
cannot be estimated from a single-arm study. Also, it cannot
be derived from trial endpoints that are on a continuous scale
(e.g., patient blood pressure, cholesterol level, duration of
relapse-free survival), as a time to event (e.g., time to first
hospitalization,timetodeath),orasanRRR.Inaddition,ifthe
experimental intervention is evaluated against a control group
that is not the standard of care in a particular institution, then
the NNTestimate would not be sufficiently meaningful.
Number needed to harm
A closely related concept to the NNT is the NNH, which can
be used to compare the safety profile of two treatments
studied in a clinical trial [12]. As with the NNT, the NNH
is treatment-specific and must always be relative to a com-
parator over a predefined time period. As an illustration,
using the previous hypothetical example where the NNT
with the new chemotherapy was 10, suppose that the abso-
lute difference in the development of deep vein thrombosis
was 10 % lower in the control group. For every 10 patients
that we treat with the new agent, we avoid one patient with a
disease recurrence (i.e., NNT010). However, we would also
expect the development of one additional patient developing
a deep vein thrombosis with the 10 treatments with the new
therapy (i.e., NNH010). Clinicians must, therefore, consid-
er both the NNT and NNH when interpreting the results of
randomized trials and deciding on therapy for their patients.
Limitations of NNT and NNH
NNT and NNH are both very useful for understanding the
findings from randomized trials, but there are some caveats
that must be taken into consideration [10, 12]. If the formu-
las are not used with sufficient rigor, the conclusions will be
misleading. Here are some major pitfalls one may encounter
when calculating and interpreting such analyses. NNT and
NNH are disease-specific and comparisons across clinical
conditions should not be performed. As an illustration, an
NNT of 10 for preventing a breast cancer relapse is not
comparable to an NNT of 5 for preventing febrile neutrope-
nia with granulocyte colony-stimulating factor (G-CSF). It
would be erroneous to conclude that G-CSF is preferred to
Table 1 The standard 2×2 contingency table
Outcome
Treatment Event No event
Experimental Cell110a Cell210bn 0a+b
Control Cell120c Cell220dm 0c+d
N0a+b+c+d
1354 Support Care Cancer (2012) 20:1353–1360the new chemotherapy that reduces breast cancer recurren-
ces. The only situation where NNTs could be compared
across studies is when the same disease condition is being
investigated, when an identical control is used, and when the
inclusion/exclusion criteria are comparable between trials.
In addition, estimates should only be measured over the
same time period. For example, it would be inappropriate
to compare acute control of bone pain after a single fraction
of radiation therapy to an oral bisphosphonate administered
for 1 month because the time periods are not identical.
Health care decision-makers should be wary of analyses that
use unconventional measurements of time; NNT and NNH
are very straightforward equations so results that are not
reasonably intuitive should be viewed with caution.
Because NNTs and NNHs are presented as single numb-
ers, the variability of treatment benefit may not be fully
conveyed. Using confidence intervals (CI) is a way to ac-
count for this. From a practical point of view, the 95 % CI of
the NNT and NNH can be calculated by taking the recipro-
cal of the 95 % CI limits of the difference in event rates
between the experimental and control groups. For example,
if the new chemotherapy agent reduces breast cancer recur-
rences by 10 % with the 95 % CI being between 8 and 12 %,
the NNT would be 10 with a 95 % CI from 9 to 13 (i.e., 1/
0.1208.3 and 1/0.08012.5; all NNTs should be rounded up
to the nearest whole number).
One must also be aware that a calculated NNT represents
the “average” for all patients who were enrolled into the
randomized trial [10, 12]. This is helpful from an epidemi-
ological point of view, but does not fully account for the
potential differences in baseline disease risk between a
clinician’s own patient population and those who were
enrolled into the trial. Similarly, NNT assumes that a given
RRR is identical across patients with different levels of risk.
However, most of the benefit may be limited to the
intermediate- and high-risk groups.
Subgroup analyses are very common in oncology clinical
trials, but some of these analyses are not preplanned. Such
unplanned analyses are very tempting to perform following a
large trial because investigators are often interested in identi-
fying the patient subgroups where benefit is maximized.
However, performing multiple tests on a sample of data
increases the risk of identifying statistically significant results
by chance alone [8]. What is problematic in the clinical
literature is that we have no idea how many statistical tests
have been performed relative to the number that are presented
in the published paper. Furthermore, a subgroup analysis only
usesa portion ofthe originaldataand itisoften underpowered
to detect true differences between selected patient subpopula-
tions. In order to minimize these potential biases, one should
only estimate the NNTand NNH on the primary endpoint and
in subgroups that were both preplanned and have a logical
biological basis [9, 10, 12].
The final point to consider is that NNT and NNH analy-
ses are often interpreted from a public health standpoint and
can be used to guide medical resource allocation. Yet, NNT
and NNH ignore the cost to treat each patient. Therefore,
they are most useful when considered in a broader context.
Bone-targeted therapies: application of NNT and NNH
evaluations
NNT and NNH can be effectively applied to both health
policy and clinical decision-making. We will use these
Table 2 Binary clinical outcomes reported in randomized trials of adjuvant therapy in early stage cancers
Outcome Definition Expression
Early stage disease
Disease recurrence Number of patients who have redeveloped the disease at a given point in time,
after a period of being disease-free.
Exp group0a
Control group0c
Risk of recurrence Proportion of patients who have disease recurrence divided by the number
under investigation. Usually expressed as a percent.
Exp group0a/n
Control group0c/m
RR The risk of recurrence in the experimental group divided by the risk of
recurrence in the control group. Usually expressed as a percent.
[(a/n)/(c/m)]
RRR 1-RR 1−[(a/n)/(c/m)]
ARR The risk of recurrence in the experimental group minus the risk of recurrence
in the control group.
(a/n)−(c/m)
NNT The number of patients that have to be treated by the new intervention in order
to avoid one additional clinical event. In this case, a disease recurrence.
Expressed as the reciprocal of the ARR (ARR
−1).
[(a/n)−(c/m)]
−1
OR The odds of an event occurring in the experimental group divided by the odds
of an event occurring in the control group.
(a/b)/(c/d)
HR The instantaneous RR of an event per unit time for an individual in the
experimental group compared with an individual in the control group,
given that both individuals have survived to time t.
Ln[h(t)/h0(t)0b1x1+… bkxk
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and zoledronic acid, both of which are approved for the
prevention of SREs in patients with advanced breast, pros-
tate, and other disease sites [2, 3, 11].
Bone metastases are common complications in advanced
breast and prostate cancers occurring in approximately 70 and
14 % of patients, respectively [3, 17]. The SREs of clinical
concern include hypercalcemia, pathologic fractures, spinal
cord compression, radiation to bone, and surgery to bone [3].
The prevention of bony complications has been revolution-
ized by the use of bisphosphonates. When used in addition to
systemic chemotherapy, bisphosphonates have significantly
reduced and delayed the incidence of SREs. A meta-analysis
of eight breast cancer trials showed that bisphosphonate use
resulted in a 17 % relative reduction in the risk of developing
anSRE[18].The bisphosphonates currently inclinicaluse for
the prevention of SREs include zoledronic acid, pamidronate,
ibandronate, and clodronate [3].
The tumor produces various chemokines such as para-
thyroid hormone-related peptide, interleukin-8 (IL-8), and
IL-1 to stimulate osteoblasts [21]. The osteoblasts induce
the expression of the receptor activator of nuclear factor-
kappa B ligand (RANK-L), which in turn induces osteoclast
activity leading to increased bone resorption [14, 24]. In-
creased bone resorption causes the release of factors that
favor the growth of malignant tumor cells [14, 24].
For many years, zoledronic acid has been the standard of
care in multiple myeloma and patients with bone metastases
from solid tumors including breast and prostate cancers, in
conjunction with standard antineoplastic therapy [22, 23].
Denosumab is a monoclonal antibody that binds to RANK-
L, thereby inhibiting its action [24]. It was recently shown
via large randomized double-blind trials that denosumab
significantly delays time to first SRE in prostate and breast
cancers compared with zoledronic acid [7, 26]. In patients
with other solid tumors and multiple myeloma, the drugs
were shown to be equivalent in the median time to first SRE
[11]. However, it should be pointed out that the mortality
with denosumab was also higher than zoledronic acid in a
subgroup analysis of patients with multiple myeloma. As a
result, denosumab is not indicated for multiple myeloma [6].
Application of NNT and NNH to zoledronic acid
and denosumab
Methods
A computer literature search of PubMed was conducted
from January 2006 to January 2012 to identify randomized
trials comparing denosumab to zoledronic acid for the pre-
vention of SREs in patients with advanced breast, prostate,
and other cancer sites. Search terms consisted of
“{zoledronic acid}, AND {denosumab} AND {randomized
clinical trial} AND {advanced breast cancer} OR {ad-
vanced prostate cancer} OR {cancer}.” The inclusion crite-
ria for trial acceptance consisted of the following: published
in a peer-reviewed English language journal, the trial must
have utilized a parallel group randomized design, had to
have been double-blinded, and the primary or secondary
endpoint had to be the presentation of SREs defined as
hypercalcemia, pathologic fractures, spinal cord compres-
sion, radiation to bone, and surgery to bone.
Results
A randomized trial meeting the inclusion criteria was iden-
tified for the prevention of SREs in advanced breast and
prostate cancers and in patients with other solid tumors or
multiple myeloma [7, 11, 26]. The trials reported clinical
and safety outcomes in terms of binary estimates, which was
required for the NNT and NNH analysis.
Breast cancer
In a study reported by Stopeck et al., denosumab was com-
pared to zoledronic acid in 2,046 patients with advanced
breastcancer.Eligiblepatientsrandomizedonetoonetoeither
denosumab 120 mg subcutaneous injection or to intravenous
injection of zoledronic acid 4 mg adjusted for creatinine
clearance [26]. The study was a double-blinded non-
inferioritytrialandtreatmentwasadministeredevery4weeks.
The primary endpointwas time tofirst SRE. The investigators
reportedthatdenosumabdelayedtimetofirstSRE(HR00.82,
p00.01) relative to zoledronic acid [26]. Over the 34-month
study duration, the proportion of denosumab and zoledronic
acid patients developing at least one SRE was 30.7 and
36.5 %, respectively, for an absolute difference of 5.8 %. This
absolute difference corresponds to an NNT of 18. Therefore,
18 patients would have to be treated with denosumab as an
alternative to zoledronic acid for up to 34 months in order to
avoid one patient developing an SRE (Table 3). To avoid a
pathologic fracture and the need for radiation therapy to bone,
approximately 39 and 27 patients would need to be treated
with denosumab, respectively.
Toxicity differences between the two drugs also need to
be considered. This can be accomplished through the deter-
mination of the NNH. Fewer patients in the trial developed
acute drug reactions and renal toxicity with denosumab
(Table 4). In addition, there was a reduction in the number
of treatment discontinuations due to adverse events in the
denosumab group (9.6 vs. 12.3 %). In contrast, there were
more patients developing osteonecrosis of the jaw (ONJ)
and hypocalcemia. Therefore, the NNH for ONJ and hypo-
calcemia were 167 and 48 for denosumab, respectively
1356 Support Care Cancer (2012) 20:1353–1360(Table 4). In other words, for every 167 patients that are
treated with denosumab instead of zoledronic acid, a clini-
cian should expect up to four additional hypocalcemic epi-
sodes and one additional ONJ event.
In today’s climate of global economic recession and
fiscal restraint, drugs’ costs also need to be taken into
consideration. The acquisition cost of denosumab dose is
approximately twice that of zoledronic acid in the USA.
Combined with denosumab’s long duration of therapy to
avoid one SRE, incremental drug cost may become a barrier
to access, particularly in patients without drug insurance. To
address the cost issue, one interesting editorial suggested
that a cost-effective treatment strategy would be to offer
zoledronic acid as a first-line therapy and then switch to
denosumab using markers of bone turnover to identify
patients who are most likely to benefit [27]. Notwithstand-
ing, cost will remain a central question surrounding the
selection of bone-targeting therapies.
Prostate cancer
In the trial by Fizazi et al., which compared zoledronic acid to
denosumab in prostate cancer, 1,901 patients meeting the
eligibility criteria were randomized one to one to either
denosumab 120 mg subcutaneous injection or to intravenous
injection of zoledronic acid 4 mg adjusted for creatinine
clearance [7]. The study was a double-blinded non-
inferioritytrialandtreatmentwasadministeredevery4weeks.
The primary endpoint was time to first SRE. Patients random-
izedtoreceivedenosumabhadalongertimetofirstSRE(20.7
vs. 17.1 months; HR00.82, p00.008).
Over the 41-month study duration, the proportion of deno-
sumab and zoledronic acid patients developing at least one
SRE was 35.9 and 40.6 %, respectively, for an absolute
difference of 4.7 %. This absolute difference corresponds to
an NNT of 22. Therefore, 22 advanced-stage prostate cancer
patients would have to be treated with denosumab as an
alternative to zoledronic acid for up to 41 months to avoid
one patient developing an SRE (Table 3). To avoid a patient
needingbonesurgeryorradiationtobone,317and37patients
would need to be treated, respectively. Similarly, to avoid a
single patient developing a spinal cord compression or path-
ologic fracture, approximately 96 and 163 patients would
need to be treated with denosumab, respectively (Table 3).
Denosumab was also safer than zoledronic acid in terms of
acute drug reactions and renal toxicity. However, as was the
case in breast cancer patients, there were more ONJ and hypo-
calcemic events with denosumab, with the respective NNH
Table 3 NNT analysis for
denosumab as an alternative to
zoledronic acid
Dmab denosumab, ZA zole-
dronic acid, MM multiple mye-
loma, NA not applicable
aReciprocal of the percent differ-
ence calculates the number of
patients that need to be treated
with denosumab in place of zole-
dronic acid in order to avoid one
additional event. All NNT esti-
mates were rounded to the near-
est whole number
bAn NNT could not be calculat-
ed because bone surgeries and
cord compressions were at a
higher incidence in patients trea-
ted with denosumab
Endpoints Dmab ZA Percent difference in
event rate (ZA−Dmab)
NNT
a
Breast cancer
Sample size 1,026 1,020
Any SRE 30.7 % 36.5 % 5.8 % 18
Type of SRE
Bone surgery 1.2 % 0.8 % −0.4 % NA
b
Cord compression 0.9 % 0.7 % −0.2 % NA
b
Fracture 20.7 % 23.3 % 2.6 % 39
Radiation to bone 8.0 % 11.7 % 3.7 % 27
Prostate cancer
Sample size 950 951
Any SRE 35.9 % 40.6 % 4.7 % 22
Type of SRE
Bone surgery 0.1 % 0.4 % 0.3 % 317
Cord compression 2.7 % 3.8 % 1.1 % 96
Fracture 14.4 % 15.0 % 0.6 % 163
Radiation to bone 18.6 % 21.3 % 2.7 % 37
Other solid tumors and MM
Sample size 886 890
Any SRE 31.4 % 36.3 % 4.9 % 21
Type of SRE
Bone surgery 1.5 % 2.1 % 0.6 % 167
Cord compression 2.7 % 2.4 % −0.3 % NA
b
Fracture 13.8 % 15.6 % 1.8 % 56
Radiation to bone 13.4 % 16.2 % 2.8 % 36
Support Care Cancer (2012) 20:1353–1360 1357being 68 and 15 (Table 4). There was also an increase in drug
discontinuation from adverse events in patients receiving treat-
ment with denosumab. The NNH for treatment discontinua-
tions with denosumab was estimated to be 36 (Table 4). In
other words, for every 36 prostate cancer patients who start
therapy with denosumab instead of zoledronic acid, one patient
will have to stop therapy because of an adverse event.
Other disease sites and multiple myeloma
Denosumab was also compared to zoledronic acid in patients
with advanced solid tumors (excluding breast and prostate) as
wellasthosewithmultiplemyeloma[11].Thetrialdesignand
dosage of denosumab and zoledronic acid were identical to
the formertwo trials. Overall,1,776 patientswererandomized
to receive bone-targeted therapy over a 34-month trial hori-
zon. The investigators reported equivalence in time to first
SRE between drugs [12]. The proportion of patients develop-
ing any SRE was 31.4 and 36.3 % in the denosumab and
zoledronic acid groups, respectively (the p value was not
significant). The ARR of 4.9 % corresponded to an NNT of
21 (Table 3). Therefore, 21 patients would need to be treated
with denosumab for up to 34 months in order to avoid one
patient developing an SRE. Technically speaking, NNTs
should not be determined for differences that are not statisti-
cally significant. However, they were applied to the trial
results for comparative purposes.
When focusing on specific SREs, the NNT to avoid bone
surgery, a pathologic fracture, and radiation to bone were
167, 56, and 36, respectively (Table 3). Patients treated with
denosumab had a similar incidence of ONJ and a lower
number of acute reactions, renal complications, as well as
serious toxicities requiring discontinuation of therapy. How-
ever, the frequency of hypocalcemia was higher in the
denosumab group, resulting in an NNH of 5 (Table 4).
Discussion
The methods of NNTand NNH were described as a means of
understanding trial results from an epidemiological viewpoint
andsettingexpectationsforclinicaloutcomes.Toillustratethe
methodology, these evaluations were applied towards bone-
targeted therapies indicated for the prevention of SREs in
advanced-stage cancer patients. The NNT to prevent one
patient developing any SRE with denosumab in breast cancer,
prostate cancer, and advanced solid tumors/multiple myeloma
were 18, 22, and 21 over a 2- to 3- year time horizon.
Table 4 NNH analysis for
denosumab as an alternative to
zoledronic acid
Dmab denosumab, ZA zole-
dronic acid, MM multiple mye-
loma, ONJ osteonecrosis of the
jaw, NA not applicable
aReciprical of the percent differ-
ence in side effect rates calcu-
lates the NNH. All NNH
estimates were rounded to the
nearest whole number
bAn NNH could not be calculat-
ed because the event rates were
at a lower incidence in patients
treated with denosumab
Endpoints Dmab ZA Percent difference in
event rate (ZA−Dmab)
NNH
a
Breast cancer
Sample size 1,020 1,013
Off drug due to adverse event 9.6 % 12.3 % −2.7 % NA
b
Type of event
ONJ 2.0 % 1.4 % 0.6 % 167
Hypocalcemia 5.5 % 3.4 % 2.1 % 48
Renal toxicity 4.9 % 8.5 % −3.6 % NA
b
Acute reactions 10.4 % 27.3 % −16.9 % NA
b
Prostate cancer
Sample size 943 918
Off drug due to adverse event 17.4 % 14.6 % 2.8 % 36
Type of event
ONJ at 2 years 2.3 % 0.8 % 1.5 % 68
Hypocalcemia 12.8 % 5.8 % 7.0 % 15
Renal toxicity 14.7 % 16.1 % −1.4 % NA
b
Acute reactions 8.4 % 17.8 % −9.4 % NA
b
Other solid tumors and MM
Sample size 878 878
Off drug due to adverse event 10.4 % 12.4 % −2.1 % NA
b
Type of event
ONJ 1.1 % 1.3 % −0.2 % NA
b
Hypocalcemia 10.8 % 5.8 % 5.0 % 5
Renal toxicity 8.3 % 10.9 % −2.6 % NA
b
Acute reactions 6.9 % 14.5 % −7.6 % NA
b
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risks, and the incremental drug cost of long-term therapy with
denosumab. The trial data also suggest that oncologists can
expect slightly more cases of ONJ and hypocalcemia with
denosumabinpatientswithbreastandprostatecancers[7,26].
However, this would be compensated with fewer cases of
acute drug reactions and renal toxicity.
The question of cost-effectiveness becomes important in
the selection of bone-targeted therapy. The costs of treating
an SRE have been estimated to be between $12,000 and
$14,000 per patient [4, 14]. Therefore, denosumab may be a
cost-effective alternative to zoledronic acid if it can avoid
enough high-cost SREs. Recently, two economic evalua-
tions evaluated the cost-effectiveness of denosumab in pros-
tate and breast cancer patients. The first study used a
Markov modeling approach to estimate the incremental cost
per SRE avoided with denosumab in advanced-stage pros-
tate cancer patients [28]. The study was conducted from the
US payer perspective. The investigators estimated that the
incremental total direct costs per SRE avoided with deno-
sumab instead of zoledronic acid were $71,027 for 1 year
and $51,319 for 3 years of therapy [28]. In a similar mod-
eling analysis conducted in advanced-stage breast cancer
patients, Carter et al. reported that it would cost $643,726
with denosumab to achieve one additional quality-adjusted
life year over zoledronic acid [1]. Such an incremental cost-
effectiveness ratio would be beyond the cost-effectiveness
thresholds in most countries [5]. However, these two studies
are in fact computer simulations of real-world clinical
events. It waits to be seen with the collection of prospective
observational data if denosumab is indeed able to avoid
enough SREs to overcome the added drug cost.
It is of interest to note that an NNT analysis comparing
denosumab to zoledronic acid in advanced solid tumors/
multiple myeloma patients was also reported at the 2011
ASCO meeting [19]. The method used to calculate the NNT
was unique and not consistent with the accepted approach
[10, 12, 25]. In that analysis, the NNT for denosumab was
calculated from the first SRE and again from the first and
subsequent SREs. The NNToutcomes were then reported in
terms of patient-years instead of individual patients. It was
reported that the NNT for denosumab to prevent the first
SRE event was approximately 9.9 and to prevent the subse-
quent SRE per year was 10. Upon closer inspection of their
methodology, it appears that the investigators used the trial-
reported RRR abstracted for the HR to calculate SREs.
However, it is quite clear from the supporting literature that
the ARR calculated from a binary trial endpoint is the
appropriate parameter that should be used to calculate an
NNT [10, 12, 25]. By definition, an NNTcalculated from an
RRR is not the number of patients that need to be treated to
avoid one patient developing the event. As a result, the use
of NNTs, as reported by Richardson et al., should be
interpreted with caution [19]. Similar NNT analyses using
this same methodology have also been done for the meta-
static breast and prostate cancer studies comparing denosu-
mab to zoledronic acid for the prevention of SREs [15, 16].
Similar caution should also be exercised in interpreting the
NNT results from these studies.
There are a number of limitations in the current analysis
that need to be acknowledged. The difference in the specific
types of SREs avoided (e.g., fractures) was not statistically
significant between the two drugs. Therefore, on technical
grounds, the NNT to avoid each of these events with deno-
sumab should not have been calculated because the true
value would approach infinity, consistent with the lack of
statistically significant differences in the subgroup analysis.
Patient quality of life is an important component in studies
evaluating bone-targeted therapies. However, the ability to
prevent an SRE detected during a clinical trial does not
necessarily correlate with quality of life improvements be-
cause many of these events may be asymptomatic. Conse-
quently, NNTs are not able to capture differences in quality
of life between the two competing therapies.
In conclusion, the NNT and NNH are effective ways of
interpreting the data from randomized clinical trials. Both
NNT and NNH are useful, but represent only one compo-
nent in the overall decision-making process. Decision-
makers must also consider drug safety, patient preferences,
incremental drug cost, cost-effectiveness, and their own
clinical judgment and treatment guidelines before offering
a new agent to patients. Nonetheless, NNT and NNH anal-
ysis can make an important contribution towards the selec-
tion of optimal therapy for cancer patients, particularly in
the case of bone-targeted therapies.
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